ストックスクリーナーアプリを入手
2.57
0.00%
0.00
アフターアワーズ：
2.57
Repare Therapeutics Inc (RPTX) 最新ニュース
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
Repare Therapeutics Announces Gilead Acquisition of RP-3467 for Up to $30 Million - citybiz
Repare Therapeutics announces CSO resignation and transition plan - MSN
Repare Therapeutics Sells RP-3467 Program to Gilead - The Globe and Mail
Aug Drivers: How buybacks impact Repare Therapeutics Inc stock valueMarket Movement Recap & Weekly High Return Stock Forecasts - moha.gov.vn
Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact - Investing.com Nigeria
Repare Therapeutics Signs Asset Purchase Agreement With Gilead Sciences - TradingView — Track All Markets
RPTX stock soars pre-market after Gilead agrees to acquire investigational cancer drug - MSN
Gilead to buy Repare Thera’s cancer candidate for up to $30M - MSN
Gilead Sciences to acquire Repare’s RP-3467 - Pharmaceutical Technology
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Stocktwits
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million By Investing.com - Investing.com Nigeria
Repare’s Sale Sparks Concerns: Time to Sell? - StocksToTrade
Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX) - MarketBeat
Gilead Sciences Acquires Polθ ATPase Inhibitor RP-3467 for $30 Million - El-Balad.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise - marketscreener.com
Repare Therapeutics Faces Scrutiny Amid Sale Deal - timothysykes.com
Repare Therapeutics (RPTX) Surges on $30M Asset Sale to Gilead - GuruFocus
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug - Investing.com
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million - Benzinga
Repare Therapeutics Sells Polymerase Theta ATPase Inhibitor To Gilead For Up To $30Mln - Nasdaq
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Investing News Network
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset - GuruFocus
Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead - marketscreener.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million - Investing.com
Repare Therapeutics Announces Acquisition Of Pol? ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration - marketscreener.com
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Bluefield Daily Telegraph
Order Flow Trends Show Accumulation in Graphite India LimitedPortfolio Risk Assessment & Free Powerful Profit Generation - earlytimes.in
Will Repare Therapeutics Inc. stock gain from lower inflationEarnings Surprise Analysis & Our Picks = Your Future Gains - bollywoodhelpline.com
Can Repare Therapeutics Inc. stock double in next 5 yearsJuly 2025 Weekly Recap & Daily Oversold Bounce Ideas - Улправда
Repare Therapeutics Announces Resignation of Chief Scientific Officer - TradingView — Track All Markets
Repare Therapeutics Inc. Announces Resignation Ofmichael Zinda as Chief Scientific Officer, Effective December 31, 2025 - marketscreener.com
Why Repare Therapeutics Inc. stock is considered a top pickWeekly Market Report & Stepwise Swing Trade Plans - DonanımHaber
XenoTherapeutics to acquire Repare Therapeutics for $1.82 p/s plus one CVR - MSN
Why Repare Therapeutics Inc. stock is in analyst buy zone2025 Geopolitical Influence & Safe Swing Trade Setups - Улправда
Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights - Sahm
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-RPTX, FRGE, CSGS, FIZN - The Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN - Benzinga
Repare Therapeutics Inc. (NASDAQ:RPTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Repare Therapeutics announces shareholder meeting for acquisition approval - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN - Sahm
Repare Therapeutics Announces Shareholder Meeting for Acquisition Approval - TipRanks
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Repare Therapeutics (RPTX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Levels Update: Will Repare Therapeutics Inc. stock gain from lower inflation2025 AllTime Highs & Expert Verified Movement Alerts - moha.gov.vn
Will Repare Therapeutics Inc. stock deliver strong dividend growth2025 Momentum Check & Risk Adjusted Swing Trade Ideas - Newser
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerRPTX, AXTA, WTG and SEMR - Eastern Progress
Risk Report: Why Repare Therapeutics Inc. stock is in analyst buy zone2025 Price Momentum & Daily Price Action Insights - moha.gov.vn
Halper Sadeh LLC Encourages THS, RPTX, AXTA Shareholders to Contact the Firm to Discuss Their Rights - Sahm
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):